INS and diabetes mellitus: These medications induce significant weight loss due to their role in regulating glucose by decreasing gastric emptying, stimulating glucose-dependent insulin secretion, suppressing glucagon secretion, and decreasing appetite. GLP-1RA have shown success in metabolic syndromes due to their benefits; semaglutide and liraglutide have received FDA approval for weight loss even without the presence of diabetes [8]. Furthermore, GLP-1RA have a minimal incidence of causing hypoglycemia.